| Product No | EMEA/H/C/004650 |
|---|---|
| Brand Name | Tremelimumab AstraZeneca |
| Nonproprietary Name | tremelimumab |
| API | Tremelimumab |
| ATC Code | L01FX20 |
| Indications | Tremelimumab AstraZeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations. |
| Orphan Drug | no |
| Generics | no |
| Marketing Authorization Holder | AstraZeneca AB |
| Status | Authorised(授权) |
| Authorization Date | 2023-02-20 |
| Version | 0 |
| Condition Approval | no |
| Exceptions | no |
| Biosimilar | no |
| Details | 查看 (公众评估报告、授权细节、产品规格/剂型、标签、历史评估信息) |
Extended Information